Haleon plc
Haleon plc (HLN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · HLN · as of Jun 8, 2026
Key Statistics
Explore Haleon plc Data
hln stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 75.0%
The HLN analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $10.20, representing +11.84% upside from the current price of $9.12.
Competitors & Peers
hln competitorsHLN
A
ALC
BDX
CAH
HUMStock Performance
Full HistoryAbout Haleon plc
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific…
what is haleon plc · hln stock overview · haleon plc company profile · who is haleon plc ceo · hln NYSE · haleon plc headquarters · haleon plc business segments
About Stock Overview & Key Data
Haleon plc (HLN) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NYSE since Jul 25, 2022. As of the latest trading session, HLN stock price is $9.12, with a market capitalization of $40.5B. The stock has returned -16.18% over the past 12 months and -9.79% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Haleon plc stock is Buy, with an average 12-month price target of $10.20. In fiscal year 2025, Haleon plc reported revenue of $10.8B and net income of $1.6B. For detailed data — including Haleon plc revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Haleon plc (HLN) stock price is $9.12. The stock is traded on NYSE under the ticker symbol HLN. The 52-week range is $8.65 – $11.28.